NCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
Clinical Trials
12 trialsNCT01779206 2025-04-08
ADAPT
West German Study Group
Phase 2/3 Completed
NCT02641847 2024-01-25
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University
Phase 2/3 Active not recruiting
NCT05253066 2022-02-23
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Shengjing Hospital
Phase 2/3 Unknown
NCT04576143 2021-08-12
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Recruiting
NCT01907529 2019-08-09
TENDENCY
Hebei Medical University Fourth Hospital
Phase 2/3 Unknown
NCT01216644 2019-06-19
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Phase 2/3 Completed
NCT03349177 2017-11-21
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2/3 Unknown
NCT02871869 2017-07-17
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Xinjiang Medical University
Phase 2/3 Unknown
NCT00843934 2012-10-19
ACE500
Nihon University
Phase 2/3 Unknown
NCT00960284 2012-01-13
PACT-7
IRCCS San Raffaele
Phase 2/3 Completed
NCT00525642 2007-09-06
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Fudan University
Phase 2/3 Unknown